Cancer-free after 12 years: Why you’re hearing the C-word more often
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an emerging immunotherapy treatment known as CAR-T. From the upcoming Innovation issue, out on February 26.
Biotech entrepreneur Paul Hopper at KPD Australia. His latest venture, Chimeric, has begun a phase-one clinical trial of its CAR-T therapy in the US. Louie Douvis
Laurie Adami was 45 when she began “feeling crummy”, exhausted and plagued with constant sinus infections.
It was 2006 and the high-flying tech executive, who was juggling her career while raising a young son, was told by doctors her blood tests looked normal. Given she was a busy working mum, they opined, it was hardly surprising she was tired at the end of the day.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Technology
Fetching latest articles